Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background: Nintedanib and pirfenidone are preferred pharmacological therapies for patients with idiopathic pulmonary fibrosis (IPF). However, evidence favoring antifibrotic therapy in patients with non-IPF fibrosing interstitial lung diseases (ILD) is limited. Objective: To investigate the effects of antifibrotic therapy on disease progression, all-cause mortality, and acute exacerbation (AE) risk in patients with non-IPF fibrosing ILDs. Design: Meta-analysis. Data sources and methods: Electronic databases were searched for articles published before 28 February 2023. Studies that evaluated the efficacy of antifibrotic agents in patients with fibrosing ILDs were selected. The primary outcome was the disease progression risk, and the secondary outcomes included all-cause mortality and AE risk. The GRADE criteria were used for the certainty of evidence assessment. Results: Nine studies with 1990 participants were included. Antifibrotic therapy reduced the rate of patients with disease progression (five trials with 1741 subjects; relative risk (RR), 0.56; 95% CI, 0.42–0.75; p < 0.0001; I 2 = 0; high-certainty evidence). Antifibrotic therapy did not significantly decrease all-cause mortality (nine trials with 1990 subjects; RR, 0.76; 95% CI, 0.55–1.03; p = 0.08; I 2 = 0; low-certainty evidence). However, in patients with progressive fibrosing ILDs (PF-ILD), antifibrotic therapy decreased all-cause mortality (four trials with 1100 subjects; RR, 0.69; 95% CI, 0.48–0.98; p = 0.04; I 2 = 0; low-certainty evidence). Conclusion: Our study supports the use of antifibrotic agents in patients with PF-ILDs, which could slow disease progression and decrease all-cause mortality. Trial registration: This study protocol was registered with PROSPERO (registration number: CRD42023411272).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nintedanib was also shown in the INBUILD study and subsequent meta-analyses to reduce FVC decline in non-IPF progressive pulmonary fibrosis [32,33,45].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A series of systematic reviews and meta-analyses confirmed the efficacy and safety of pirfenidone in the treatment of IPF [27–33].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957 · cited 1×
“This is roughly consistent with the consensus recommendations, 28 and could help identify patients whose disease has progressed similarly.”
ResultNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629 · cited 4×
“Six trials 7–10, 21 , 24 We found no significant publication bias based on the results of the funnel plots and Egger’s test ( p = 0.598).”
BackgroundMethodInfluentialWijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Behr, J., Prasse, A., Kreuter, M., Johow, J., Rabe, K. F., Bonella, F., Bonnet, R., Grohe, C., Held, M., Wilkens, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30554-3 · Cited by 522
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388
Goh, N. S., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40130 · Cited by 354 · cited 9×
“We also found that antifibrotic treat-ment might decrease all-cause mortality in patients with PF-ILDs, although the certainty of the evidence is low.”
BackgroundInfluentialGeorge, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349 · cited 1×
“6 Considering the pathophysiological similarities between these diseases, researchers have speculated that non-IPF-fibros-ing ILDs would have similar treatment responses to antifibrotic agents.”
BackgroundFarrah, K., Young, K., Tunis, M. C., & Zhao, L. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1172-8 · Cited by 246
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220 · cited 1×
“2 5 As for other fibrosing ILDs, while appropriate management is efficacious in improving or stabilizing clinical symptoms, some patients still suffer from progressive fibrosis.”
BackgroundHighland, K. B., Distler, O., Kuwana, M., Allanore, Y., Assassi, S., Azuma, A., Bourdin, A., Denton, C. P., Distler, J. H. W., Hoffmann-Vold, A. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30330-1 · Cited by 217
Solomon, J. J., Danoff, S. K., Woodhead, F. A., Hurwitz, S., Maurer, R., Glaspole, I., Dellaripa, P. F., Gooptu, B., Vassallo, R., Cox, P. G., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00260-0 · Cited by 216
Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A., & Kamil, H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01783-1 · Cited by 209 · cited 2×
“11 However, our meta-analysis included more studies, and the subgroup analysis suggested that mortality decreased significantly in patients with PF-ILDs treated with antifibrotic agents.”
ResultEffect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome
Gahl, W. A., Brantly, M., Troendle, J., Avila, N. A., Padua, A., Montalvo, C., Cardona, H., Anton Calis, K., & Gochuico, B. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00044-6 · Cited by 203 · cited 1×
“Six trials 7–10, 21 , 24 We found no significant publication bias based on the results of the funnel plots and Egger’s test ( p = 0.598).”
MethodInfluentialBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Progression of fibrosing interstitial lung disease
Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 185
Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis
Gimenez, A., Storrer, K., Kuranishi, L., Soares, M. R., Ferreira, R. G., & Pereira, C. A. C. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210035 · Cited by 184 · cited 2×
“27 With regard to PF-ILDs, the guideline committee merely made a ‘conditional recommendation’ for the use of nin-tedanib and suggested the need for more research.”
BackgroundMethodMatteson, E. L., Kelly, C. A., Distler, J. H. W., Hoffmann‐Vold, A., Seibold, J. R., Mittoo, S., Dellaripa, P. F., Aringer, M., Pope, J. E., Distler, O., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42075 · Cited by 148
Li, T., Guo, L., Chen, Z., Gu, L., Sun, F., Tan, X., Chen, S., Wang, X., & Ye, S. (2016) · Scientific Reports · doi:10.1038/srep33226 · Cited by 117
Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Ghazipura, M., Mammen, M. J., Bissell, B. D., Macrea, M. M., Herman, D. D., Hon, S. M., Kheir, F. M., Khor, Y. H., Knight, S. L., Raghu, G., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-342oc · Cited by 87 · cited 1×
“12,13 Therefore, we conducted this meta-analysis to further evaluate the efficacy of antifibrotic drugs in non-IPF-fibrosing ILDs.”
MethodPirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis
O’Brien, K., Troendle, J. F., Gochuico, B. R., Markello, T. C., Salas, J., Cardona, H., Yao, J., Bernardini, I. M., Hess, R. A., & Gahl, W. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.02.003 · Cited by 82
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F. C., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01857-y · Cited by 71 · cited 1×
“30 Currently, it is difficult to determine which agent is superior, and further studies are required.”
BackgroundNintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Ghazipura, M., Mammen, M. J., Herman, D. D., Hon, S. M., Bissell, B. D., Macrea, M. M., Kheir, F. M., Khor, Y. H., Knight, S. L., Raghu, G., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-343oc · Cited by 69 · cited 1×
“12,13 Therefore, we conducted this meta-analysis to further evaluate the efficacy of antifibrotic drugs in non-IPF-fibrosing ILDs.”
MethodWang, J., Wang, X., Qi, X., Sun, Z.-J., Zhang, T., Cui, Y., & Shu, Q. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.871861 · Cited by 45
Belhassen, M., Dalon, F., Nolin, M., & Van Ganse, E. (2021) · Respiratory Research · doi:10.1186/s12931-021-01714-y · Cited by 38
Campochiaro, C., Luca, G. D. D., Lazzaroni, M. G., Armentaro, G., Spinella, A., Vigone, B., Ruaro, B., Stanziola, A. A., Benfaremo, D., Lorenzis, E. D., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002850 · Cited by 38 · cited 1×
“Although the SENSCIS trial and another multicenter real-world study showed that nintedanib could slow the decline in lung function in patients with SSc-ILD, 8,31 significant adverse gastrointestinal events should also be considered.”
Azuma, A., Chung, L. S., Behera, D., Chung, M. P., Kondoh, Y., Ogura, T., Okamoto, M., Swarnakar, R., Zeng, X., Zou, H., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.005 · Cited by 21 · cited 1×
“34 Nevertheless, whether the association between antifibrotic therapy and reduced mortality is modified by specific factors needs to be clarified in future studies.”
Background
Research works printed but not linked: 2
- Li T, 2016, Sci Rep, 6
- Campochiaro C, 2023, RMD, 9
Cited by
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“Nintedanib was also shown in the INBUILD study and subsequent meta-analyses to reduce FVC decline in non-IPF progressive pulmonary fibrosis [33,34,46].”
Qiu, Y., & Ye, W. (2025) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_132_25 · Cited by 16
“[29] A cohort study reported that compared to pirfenidone alone, the combination of pirfenidone and nintedanib significantly decreased the rate of decline in the FVC, which was accompanied by a higher risk of gastrointestinal adverse events.”
Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review
Montero, I. E., Hernández‐González, F., & Sellarés, J. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00302-5 · Cited by 15
“However, specifically in patients fulfill‑ ing the PF‑ILD criteria, antifibrotic therapy was found to reduce all‑cause mortality (RR 0.69; 95% CI 0.49–0.98; p = 0.04), although with low‑ certainty evidence [88].”
InfluentialSrivali, N., Giacomi, F. D., Moua, T., & Ryu, J. H. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.08.002 · Cited by 4
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-34071-7 · Cited by 3
“In contrast, while nintedanib has been shown to reduce FVC decline and all-cause mortality in PF-ILD 6,14,15 , data regarding its effect on acute exacerbations in this population are sparse, with only limited evidence suggesting a preventive benefit 16 .”
Metadata
- Authors
- Li, D.-Y., Liu, X., Huang, J.-Y., Hang, W.-L., Yu, G.-R., & Xu, Y.
- Affiliations
- Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
- Nanjing University of Chinese Medicine (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Department of Respiratory Medicine, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
- Corresponding author
- Xu, Yong
- Venue
- Therapeutic Advances in Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2024-01
- Volume
- 18
- Pages
- 17534666241232561-17534666241232561
- ISSN
- 1753-4658 (ISSN-L)
- 1753-4666
- PMC
- PMC10901065
- OpenAlex
- W4392249802
- Cited by
- 15
- References
- 35
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Respiratory Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NATCM’s Project of High-level Construction of Key TCM Disciplines
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- progressive fibrosing interstitial lung disease, nintedanib, pirfenidone, disease progression, all-cause mortality, acute exacerbation, idiopathic pulmonary fibrosis
- MeSH terms
- Antifibrotic Agents, Fibrosis, Humans, Prospective Studies, Randomized Controlled Trials as Topic, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.